Emyria Ltd (ASX: EMD) has announced promising 3-month follow-up clinical results for their PTSD program utilizing MDMA-assisted therapy. The interim analysis for the first eight patients showed a sustained and clinically significant reduction in PTSD symptoms, with PCL-5 scores decreasing by 29.6 points on average. Additionally, there was a statistically significant improvement in quality of life, with ReQoL-10 scores increasing by an average of 23.5 points. These results will be presented at the Euroz Healthcare Forum. The program continues to expand, driven by Real-World Data and engagement with private hospitals and payers to enhance access.

The company's program has demonstrated substantial reductions in PTSD symptoms, with patients experiencing lasting benefits. The program involves a structured approach spanning 6-16 weeks and has shown significant improvements in quality of life post-treatment. The findings suggest the potential for long-lasting therapeutic benefits and fill a critical gap in PTSD care. Emyria is also equipped to support psilocybin-assisted therapy for treatment-resistant depression, leveraging their existing infrastructure and expertise.

Investors interested in Emyria's developments in mental health treatment and drug development can explore their interactive investor hub for updates and engage with the company for more information. The company's forward-looking statements emphasize their commitment to innovation and responsible use of new treatments, highlighting the importance of safety and efficacy in their programs.